Clinical TrialCrossoverNitrous OxideNitrous OxidePlaceboCompleted

Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies

The purpose of the study aims to determine whether different concentrations of nitrous oxide (N2O) have different antidepressant effects for adults with treatment-resistant major depression.

Ask Blossom about this trial
Target Enrollment
Not specified
Study Type
Phase II interventional
Design
Randomized

Study Arms & Interventions

50% nitrous oxide

experimental

Single 1-hour inhalation of 50% nitrous oxide in oxygen

Interventions

  • Nitrous Oxide50 %
    via Inhalation• single dose• 1 doses total

    balanced with air/oxygen

25% nitrous oxide

experimental

Single 1-hour inhalation of 25% nitrous oxide in oxygen

Interventions

  • Nitrous Oxide25 %
    via Inhalation• single dose• 1 doses total

    balanced with air/oxygen

Placebo

placebo

Single 1-hour inhalation of placebo (air/oxygen)

Interventions

  • Placebo0 %
    via inhaled• single dose• 1 doses total

    air/oxygen

Study Details

Study Team

Sponsors & Collaborators

Related Publications

PaywallindividualPrimary

A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression

In a phase 2 trial, inhaled nitrous oxide at 25% concentration improved symptoms of treatment‑resistant major depression and produced fewer adverse effects than the 50% concentration.

Published
Journal
Science Translational Medicine
Authors
Nagele, P., Palanca, B. J., Gott, B., Brown, F., Barnes, L., Nguyen, T., Xiong, W., Salloum, N. C., Espejo, G. D., Lessov-Schlaggar, C. N., Jain, N., Cheng, W. W. L., Komen, H., Yee, B., Bolzenius, J. D., Janski, A., Gibbons, R., Zorumski, C. F., Conway, C. R.